Imatinib Mesylate

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Conditions

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Trial Timeline

Oct 1, 2003 → Feb 1, 2007

NCT ID

NCT00154349

About Imatinib Mesylate

Imatinib Mesylate is a phase 2 stage product being developed by Novartis for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00154349. Target conditions include Philadelphia Chromosome Positive Acute Lymphocytic Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Chromosome Positive Acute Lymphocytic Leukemia were approved

Approved (2) Terminated (1) Active (5)

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

✅NilotinibNovartisApproved

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

✅AsciminibNovartisApproved

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742299	Approved	Active	Mar 26, 2013	Apr 21, 2033	GIST and CML
NCT00867113	Phase 2	Completed	Jul 22, 2009	Dec 20, 2016	Gastrointestinal Stromal Tumor (GIST)
NCT00732784	Phase 1	Completed	Nov 1, 2008	Dec 1, 2012	Healthy
NCT01172548	Phase 2	Completed	Aug 1, 2008	Mar 1, 2014	Gastrointestinal Stromal Tumors
NCT01483014	Phase 2	Completed	Jun 1, 2008	Jan 1, 2012	Gastrointestinal Stromal Tumors
NCT00684411	Phase 2	Completed	Jun 1, 2008	Oct 1, 2013	T Cell Non-Hodgkin Lymphoma
NCT01545427	Phase 2	Terminated	Apr 1, 2008	Dec 1, 2008	Scleroderma
NCT00479934	Phase 2	Completed	Dec 1, 2007	Dec 1, 2010	Scleroderma, Localized
NCT00677092	Phase 2	Completed	Dec 1, 2007	Jul 1, 2009	Nephrogenic Systemic Fibrosis
NCT00555581	Phase 2	Completed	Aug 1, 2007	Dec 1, 2011	Systemic Sclerosis
NCT00510354	Approved	Completed	Oct 1, 2006	Nov 1, 2012	Progressive Gastrointestinal Stromal Tumor
NCT00427583	Phase 2/3	Terminated	May 1, 2006	—	Malignant Peripheral Nerve Sheath Tumors
NCT00124748	Phase 3	Terminated	Jun 1, 2005	Nov 1, 2010	Leukemia, Myeloid, Chronic Phase
NCT00171899	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Chronic Myelogenous Leukemia
NCT00171912	Phase 2	Completed	Sep 1, 2004	Jan 1, 2012	Hypereosinophilic Syndrome
NCT00171977	Approved	Completed	Jul 1, 2004	—	Gastrointestinal Stromal Tumors
NCT00171938	Phase 2	Terminated	Apr 1, 2004	Jun 1, 2006	Glioblastoma
NCT00154349	Phase 2	Completed	Oct 1, 2003	Feb 1, 2007	Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
NCT00237172	Phase 2	Completed	Sep 1, 2002	—	Gastrointestinal Stromal Tumors
NCT00171860	Phase 2	Terminated	Sep 1, 2002	—	Hypereosinophilic Syndrome

Competing Products

20 competing products in Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

See all competitors

Product	Company	Stage	Hype Score
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29